Thalidomide-derived immunomodulatory drugs as therapeutic agents (Q35967301)

11 August 2017

1 reference

title

Thalidomide-derived immunomodulatory drugs as therapeutic agents (English)

1 reference

11 August 2017

0 references

Christine Galustian

1

1 reference

11 August 2017

Marie-Christine Labarthe

series ordinal

2

1 reference

11 August 2017

J Blake Bartlett

series ordinal

3

1 reference

11 August 2017

Angus G Dalgleish

series ordinal

4

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Expert Opinion on Biological Therapy

11 August 2017

1 reference

11 August 2017

4

1 reference

11 August 2017

12

1 reference

11 August 2017

1963-1970

1 reference

Role of TNF in immunopathology of leprosy

11 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Taming TNF: strategies to restrain this proinflammatory cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

The role of TNF in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide and its analogues as cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide and immunomodulatory drugs as cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.12.1963

10.1517/14712598.4.12.1963

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference